NTX-301 + temozolomide

**NTX-301 + temozolomide** is an investigational combination regimen under clinical evaluation for the treatment of certain advanced cancers, including high-grade glioma. **NTX-301** is a novel, oral hypomethylating agent (HMA), chemically known as 5-aza-4′-thio-2′-deoxycytidine, which acts as a DNA methyltransferase 1 (DNMT1) inhibitor, reactivating tumor suppressor genes by inducing DNA hypomethylation and leading to cell cycle arrest, apoptosis, and differentiation. **Temozolomide** is an alkylating agent that induces DNA damage and cytotoxicity in tumor cells. The combination is being tested particularly in IDH1-mutant high-grade glioma, as an adjuvant therapy following chemoradiation, intended to replace standard temozolomide maintenance therapy, and the aim is to improve efficacy through combined epigenetic modulation and direct cytotoxicity[1][9].